Compositions and methods for treating peripheral vascular disease
View Patent ↗The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom.
1. A method of treating or preventing intermittent claudication in a subject comprising the step of administering a therapeutically effective amount of a molecule selected from the group consisting of a glucagon-like peptide-1 (GLP-1), a biologically active fragment thereof having at least one of the following functions: regulating insulin secretion, inhibiting glucagon release, inhibiting gastric acid secretion, inhibiting gastric motility, suppressing food intake, enhancing peripheral glucose uptake, or, reducing circulating fatty acid levels, a GLP-1 receptor agonist, and an exendin.
2. A method of treating or preventing skeletal muscle injury caused by ischemia and/or reperfusion in a subject comprising the step of administering a therapeutically effective amount of a molecule selected from the group consisting of a GLP-1, a biologically active fragment thereof having at least one of the following functions: regulating insulin secretion, inhibiting glucagon release, inhibiting gastric acid secretion, inhibiting gastric motility, suppressing food intake, enhancing peripheral glucose uptake, or, reducing circulating fatty acids levels a GLP-1 receptor agonist, and an exendin.
3. The method according to claim 1 or 2 , wherein the molecule is selected from the group consisting of GLP-1(7-36)NH 2 (SEQ ID NO:4), GLP-1(7-37), exendin-3 and exendin-4.
4. The method according to claim 1 or 2 wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7-36)NH 2 (SEQ ID NO:4) and GLP-1(9-36)NH 2 (SEQ ID NO:6).
5. The method according to claim 1 or 2 , wherein the subject is also administered free radical scavengers.
6. The method according to claim 5 , wherein the free radical scavenger is selected from the group consisting of glutathione, melatonin, Vitamin E, and superoxide dismutase.
7. The method according to claim 1 or 2 , wherein the subject is also administered glucose.
8. The method according to claim 7 , wherein the subject is also administered potassium.
9. The method according to claim 1 or 2 , wherein the subject is suffering from Peripheral Vascular Disease (PVD).
10. The method according to claim 1 or 2 , wherein the subject is human.
11. The method according the claim 1 or 2 , wherein the molecule is administered by an infusion pump or by subcutaneous injection of a slow release formulation of the molecule.